Wanbury Ltd
NSE: WANBURY BSE: 524212
₹255
(18.67)%
Tue, 03 Feb 2026, 08:38 am
Market Cap7.27B
PE Ratio17.12
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KAnalysis
dividend
- Unable to calculate sustainability of dividends as Wanbury has not reported any payouts.
- Unable to evaluate Wanbury's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Wanbury's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Whilst loss making Wanbury has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 16.2% per year.
- Whilst loss making Wanbury has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
- Wanbury's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Debt is not well covered by operating cash flow (19%, less than 20% of total debt).
- Wanbury has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
- Wanbury's long term commitments exceed its cash and other short term assets.
- Irrelevant to check if Wanbury's debt level has increased considering it has negative shareholder equity.
- Wanbury is making a loss, therefore interest payments are not well covered by earnings.
- Wanbury has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- High level of physical assets or inventory.
management
- The tenure for the Wanbury board of directors is about average.
- The tenure for the Wanbury management team is about average.
misc
- Wanbury is not covered by any analysts.
past
- Wanbury used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Unable to compare Wanbury's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Wanbury does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Wanbury improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
- It is difficult to establish if Wanbury has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- Unable to compare Wanbury's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Wanbury's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Wanbury's share price is below the future cash flow value, and at a substantial discount (> 40%).
- 524212 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524212 outperformed the Market in India which returned -14.5% over the past year.
- BSE:524212 is up 14.5% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524212 is up 14.5% outperforming the market in India which returned 8% over the past month.
- Wanbury has negative assets, we can't compare the value of its assets to the IN Pharmaceuticals industry average.
- Wanbury is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Wanbury is loss making, we can't compare the value of its earnings to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800